Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Several-fold increase in risk of overanticoagulation by CYP2C9 mutations.

Clinical pharmacology and therapeutics - 1 Nov 2005

Lindh Jonatan D, Lundgren Stefan, Holm Lennart, Alfredsson Lars, Rane Anders

Abstract excerpt

OBJECTIVE: Our objective was to prospectively study the impact of CYP2C9 polymorphism (*2 and *3) on the risk of overanticoagulation during the induction phase of warfarin therapy. METHODS: Blood samples for genotyping were collected from 219 patients requiring warfarin therapy, and clinical data were prospectively collected during the first 3 weeks of medication. Patients were divided into 3 groups according to...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Warfarin
Share to Anticoagulants
Share to Aryl Hydrocarbon Hydroxylases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cytochrome P-450 CYP2C9

Share to Drug Interactions

Share to Endpoint Determination

Share to International Normalized Ratio

Source

Identifiers

PMID: 16321620
DOI: 10.1016/j.clpt.2005.08.006

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Several-fold increase in risk of overanticoagulation by CYP2C9 mutations.PMID 16321620Read ↗

Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy.Semantic proximity Read ↗

The risk of overanticoagulation in patients with cytochrome P450 CYP2C9*2 or CYP2C9*3 alleles on acenocoumarol or phenprocoumon.Semantic proximity Read ↗

Effect of polymorphisms in the cytochrome P450 CYP2C9 gene on warfarin anticoagulation.Semantic proximity Read ↗

VKORC1 and CYP2C9 genotypes and acenocoumarol anticoagulation status: interaction between both genotypes affects overanticoagulation.Semantic proximity Read ↗

CYP2C9 gene variants, drug dose, and bleeding risk in warfarin-treated patients: a HuGEnet systematic review and meta-analysis.Semantic proximity Read ↗

Effects of cytochrome P450 2C9 polymorphisms on phenprocoumon anticoagulation status.Semantic proximity Read ↗

Increased frequency of CYP2C9 variant alleles and homozygous VKORC1*2B carriers in warfarin-treated patients with excessive INR response.Semantic proximity Read ↗

Influence of cytochrome P-450 CYP2C9 polymorphisms on warfarin sensitivity and risk of over-anticoagulation in patients on long-term treatment.Semantic proximity Read ↗

Early acenocoumarol overanticoagulation among cytochrome P450 2C9 poor metabolizers.Semantic proximity Read ↗

CYP2C9 genotypes and dose requirements during the induction phase of oral anticoagulant therapy.Semantic proximity Read ↗

Acenocoumarol stabilization is delayed in CYP2C93 carriers.Semantic proximity Read ↗

Genotypes associated with reduced activity of VKORC1 and CYP2C9 and their modification of acenocoumarol anticoagulation during the initial treatment period.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.